Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Patent Board To Review Mylan's Copaxone Challenge

This article was originally published in Scrip

Executive Summary

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings for petitions filed by Mylan against two patents held by Teva on its moneymaker multiple sclerosis drug Copaxone (glatiramer acetate injection).

You may also be interested in...



Mylan Sees A Difference In Having Generic Drug User Fees

FDA is pushing forward with its review of Mylan’s ANDA for generic Advair, according to the company, which is gaining confidence that the application could receive a first round approval. The experience for that application, which has a generic drug user fee, is a clear contrast to the firm's experience with its pre-GDUFA Copaxone filing.

Mylan Confident On Advair Generic First-Round Approval

President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.

Teva Advancing Two Advair Generics With Late 2017 Target

Teva will move forward an internal generic Advair candidate and one acquired from Allergan to improve its chances of getting an interchangeable version of the market-leading asthma drug approved by FDA.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC029594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel